about
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West AfricaRecognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.Broad adaptive immune responses to M. tuberculosis antigens precede TST conversion in tuberculosis exposed household contacts in a TB-endemic setting.Immunogenic Mycobacterium africanum strains associated with ongoing transmission in The GambiaLarge-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia.Elevated serum 25-hydroxy (OH) vitamin D levels are associated with risk of TB progression in Gambian adultsInterferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.Viral Hepatitis Endemicity and Trends among an Asymptomatic Adult Population in Ho: A 5-Year Retrospective Study at the Ho Municipal Hospital, Ghana.Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation.Differential Cytokine Levels in Adults Induced by a Novel Candidate TB Boost Vaccine, MVA85A-According to Previous BCG Vaccination Status
P50
Q28473318-C3A0D6F6-0C60-4795-BAA6-8BBD4E1C46E6Q34429275-14FC6BD2-A53A-4917-B2CF-2AE117ECE966Q34551322-A5927474-1DAF-4D29-8E28-F52A8EFAAE1BQ34790516-39D49C9F-7132-4225-920E-FB140B244809Q37261907-52F3F961-71EE-4B96-A240-EDBEAEAB1565Q39067836-AA112118-1468-4E10-8C9E-631FAA02CC77Q40683285-2FB972F8-0DC7-4C09-BCB4-A6558AF07B89Q44602188-AD9E0B46-2CED-4BC0-B112-3F53EB62297CQ47096707-1CCE2A8C-F916-4BC8-870E-E08F994D71A0Q54708982-AD11CC63-07C9-4CED-AF74-71DDF132F4F0Q58818201-6E52024C-C755-41E4-9A3C-D17A9ABFC8E6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrick K. Owiafe
@ast
Patrick K. Owiafe
@en
Patrick K. Owiafe
@es
Patrick K. Owiafe
@nl
Patrick K. Owiafe
@sl
type
label
Patrick K. Owiafe
@ast
Patrick K. Owiafe
@en
Patrick K. Owiafe
@es
Patrick K. Owiafe
@nl
Patrick K. Owiafe
@sl
prefLabel
Patrick K. Owiafe
@ast
Patrick K. Owiafe
@en
Patrick K. Owiafe
@es
Patrick K. Owiafe
@nl
Patrick K. Owiafe
@sl
P106
P1153
6508148559
P21
P31
P496
0000-0002-4287-3577